Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHMA Chiasma	$3.76	$4.01	$2.77 ▼ $5.74	$217.68M	1.28	2.12 million shs	147 shs
CNCE Concert Pharmaceuticals	$8.37	$8.37	$2.66 ▼ $8.55	$401.26M	0.52	2.97 million shs	N/A
UROV Urovant Sciences	$16.24	$16.23	$7.15 ▼ $16.26	$531.75M	2.36	114,469 shs	N/A
VYNE VYNE Therapeutics	$2.30 -4.2%	$2.42	$1.67 ▼ $8.73	$32.43M	1.23	122,275 shs	11,091 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHMA Chiasma	0.00%	0.00%	0.00%	0.00%	0.00%
CNCE Concert Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
UROV Urovant Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
VYNE VYNE Therapeutics	-0.83%	-10.45%	+25.00%	+28.34%	-23.33%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHMA Chiasma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UROV Urovant Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	2.653 of 5 stars	3.5	3.0	0.0	0.0	2.3	1.7	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHMA Chiasma	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A
UROV Urovant Sciences	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	3.00	Buy	$7.38	220.65% Upside

Current Analyst Ratings

Latest UROV, CNCE, CHMA, and VYNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/29/2024	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.75

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHMA Chiasma	$1.11M	196.11	N/A	N/A	$1.59 per share	2.36
CNCE Concert Pharmaceuticals	$32.58M	12.32	N/A	N/A	$3.24 per share	2.58
UROV Urovant Sciences	N/A	N/A	N/A	N/A	($1.90) per share	N/A
VYNE VYNE Therapeutics	$420K	77.21	N/A	N/A	$6.36 per share	0.36

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHMA Chiasma	-$74.78M	-$1.43	N/A	N/A	N/A	N/A	-113.57%	-57.62%	N/A
CNCE Concert Pharmaceuticals	-$80.05M	-$3.21	N/A	N/A	N/A	N/A	-109.43%	-76.65%	N/A
UROV Urovant Sciences	-$146.74M	-$4.71	N/A	N/A	N/A	N/A	N/A	-162.90%	N/A
VYNE VYNE Therapeutics	-$28.45M	-$7.04	N/A	N/A	N/A	-6,710.38%	-77.46%	-62.93%	5/9/2024 (Estimated)

Latest UROV, CNCE, CHMA, and VYNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/29/2024	Q4 2023	VYNE VYNE Therapeutics	-$0.50	-$0.20	+$0.30	-$0.20	$0.15 million	$0.08 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHMA Chiasma	N/A	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UROV Urovant Sciences	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHMA Chiasma	N/A	7.91	7.08
CNCE Concert Pharmaceuticals	N/A	9.03	9.03
UROV Urovant Sciences	N/A	2.91	2.91
VYNE VYNE Therapeutics	N/A	12.73	12.73

Ownership

Institutional Ownership

Company	Institutional Ownership
CHMA Chiasma	61.68%
CNCE Concert Pharmaceuticals	70.63%
UROV Urovant Sciences	18.44%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
CHMA Chiasma	8.30%
CNCE Concert Pharmaceuticals	11.33%
UROV Urovant Sciences	2.70%
VYNE VYNE Therapeutics	1.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CHMA Chiasma	85	57.89 million	N/A	Not Optionable
CNCE Concert Pharmaceuticals	64	47.94 million	42.51 million	Optionable
UROV Urovant Sciences	70	32.74 million	N/A	Not Optionable
VYNE VYNE Therapeutics	10	14.10 million	13.85 million	Not Optionable

UROV, CNCE, CHMA, and VYNE Headlines

Source	Headline
	VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans finance.yahoo.com - April 13 at 8:27 AM
	Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 590.3% americanbankingnews.com - April 11 at 2:54 AM
	Acne Treatment Market Poised for Substantial Growth, Anticipated to Reach USD 16.2 Billion by 2032 pharmiweb.com - March 28 at 12:46 PM
	VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference finance.yahoo.com - March 19 at 9:08 AM
	VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference globenewswire.com - March 19 at 8:00 AM
	Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now zacks.com - March 13 at 10:56 AM
	What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock zacks.com - March 8 at 1:01 PM
	Wall Street Breakfast Podcast: NYCB Gets $1B Investment Boost seekingalpha.com - March 7 at 8:21 AM
	VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 3 at 8:59 AM
	Buy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developments markets.businessinsider.com - February 29 at 7:00 PM
	VYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update finanznachrichten.de - February 29 at 10:04 AM
	VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update globenewswire.com - February 29 at 8:00 AM
	VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium finance.yahoo.com - February 27 at 8:06 AM
	VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium globenewswire.com - February 27 at 8:00 AM
	VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference finance.yahoo.com - February 21 at 8:16 AM
	VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference globenewswire.com - February 21 at 8:00 AM
	Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock finance.yahoo.com - February 2 at 7:18 AM
	Buy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Results markets.businessinsider.com - January 10 at 4:27 PM
	Prurigo Nodularis Treatment Market Forecasts Surpassing US$ 930.9 Million by 2033-FMI Study fmiblog.com - January 4 at 12:32 AM
	VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors finance.yahoo.com - January 3 at 9:29 AM
	Investing in VYNE Therapeutics Inc [VYNE]: What You Must Know knoxdaily.com - January 1 at 10:15 AM
	VYNE Therapeutics says director Lepore buys 13K shares in co msn.com - November 20 at 3:25 PM
	Cormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Inc finance.yahoo.com - November 14 at 5:53 PM
	VYNE Therapeutics files to sell 36.27M shares for holders msn.com - November 13 at 5:35 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Chiasma

NASDAQ:CHMA

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Concert Pharmaceuticals

NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Urovant Sciences

NASDAQ:UROV

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

VYNE Therapeutics

NASDAQ:VYNE

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial